<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="../css/strict.xsl"?>
<PAGE status="unmaintained" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="../css/schema.xsd">
<TITLE>Pharma</TITLE>
<PATH>links/pharma.xml</PATH>
<DATE><YEAR>2012</YEAR><MONTH>10</MONTH><DAY>20</DAY></DATE>
<CONTENT>
<LLIST>
  <ITEM><SLIST>
    <ITEM><BLIST><TITLE>Pharma companies</TITLE>
      <ITEM><X><T>Alcon</T><A>http://www.alcon.com</A><L>en</L><F>HTML</F></X></ITEM>
      <ITEM><X><T>Allergan</T><A>http://www.allergan.com</A><L>en</L><F>HTML</F></X></ITEM>
      <ITEM><X><T>Bayer</T><A>http://www.bayerhealthcare.com</A><L>en</L><F>HTML</F></X></ITEM>
      <ITEM><X><T>GlaxoSmithKline</T><A>http://www.gsk.com</A><L>en</L><F>HTML</F></X></ITEM>
      <ITEM><X><T>Ipsen</T><A>http://www.ipsen.com</A><L>en</L><F>HTML</F></X></ITEM>
      <ITEM><BLIST><TITLE><X><T>Johnson &amp; Johnson</T><A>http://www.jnj.com</A><L>en</L><F>HTML</F></X></TITLE>
        <ITEM><X><T>Cordis</T><A>http://www.cordis.com</A><L>en</L><F>HTML</F></X></ITEM>
      </BLIST></ITEM>
      <ITEM><X><T>Merck &amp; Co.</T><A>http://www.merck.com</A><L>en</L><F>HTML</F></X></ITEM>
      <ITEM><X><T>Merck KGaA</T><A>http://www.merck.de</A><L>en</L><F>HTML</F></X></ITEM>
      <ITEM><X><T>Novartis</T><A>http://www.novartis.com</A><L>en</L><F>HTML</F></X></ITEM>
      <ITEM><X><T>Pfizer</T><A>http://www.pfizer.com</A><L>en</L><F>HTML</F></X></ITEM>
      <ITEM><X><T>Laboratoires Pierre Fabre</T><A>http://www.pierre-fabre.com</A><L>fr</L><F>HTML</F></X></ITEM>
      <ITEM><X><T>Roche</T><A>http://www.roche.com</A><L>en</L><F>HTML</F></X></ITEM>
      <ITEM><X><T>Sanofi-Aventis</T><A>http://www.sanofi-aventis.com</A><L>en</L><F>HTML</F></X></ITEM>
    </BLIST></ITEM>
    <ITEM><BLIST><TITLE>Medical device companies</TITLE>
      <ITEM><X><T>Sorin Group</T><A>http://www.sorin.com</A><L>en</L><F>HTML</F></X></ITEM>
      <ITEM><X><T>Symbios</T><A>http://www.symbios.ch</A><L>en</L><F>HTML</F></X></ITEM>
    </BLIST></ITEM>
  </SLIST></ITEM>
  <ITEM><BLIST><TITLE>Articles</TITLE>
    <ITEM><ARTICLE><X quality='2'><T>Les politiques et processus d'innovation de m&#xE9;dicaments</T><A>http://www.canal-u.fr/canalu/producteurs/universite_de_tous_les_savoirs/dossier_programmes/les_conferences_de_l_annee_2004/les_nouvelles_therapies_soigner_demain/les_politiques_et_processus_d_innovation_de_medicaments</A><L>fr</L><F>Flash Video</F><DURATION><HOUR>1</HOUR><MINUTE>6</MINUTE><SECOND>4</SECOND></DURATION></X><AUTHOR><FIRSTNAME>G&#xE9;rard</FIRSTNAME><MIDDLENAME>Le</MIDDLENAME><LASTNAME>Fur</LASTNAME></AUTHOR><DATE><YEAR>2004</YEAR><MONTH>1</MONTH><DAY>13</DAY></DATE><COMMENT>After a short introduction describing the different phases of a clinical trial, G&#xE9;rard Le Fur describes the different strategies to discover new drugs.</COMMENT></ARTICLE></ITEM>
    <ITEM><ARTICLE><X><T>Inside Andy Grove's World of Bio-IT</T><A>http://www.bio-itworld.com/issues/2007/dec-jan/first-base-andy-grove/</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Kevin</FIRSTNAME><LASTNAME>Davies</LASTNAME></AUTHOR><DATE><YEAR>2007</YEAR><MONTH>12</MONTH><DAY>17</DAY></DATE><COMMENT>Andy Grove is very critical toward the pharma industry. But drugs are probably more complex than chips&#x2026;</COMMENT></ARTICLE></ITEM>
    <ITEM><ARTICLE><X><T>Roche Targets Diabetes to Replace Cancer Drug Sales (Update3)</T><A>http://www.bloomberg.com/apps/news?pid=newsarchive&amp;sid=axBTlyG8BBXw</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Dermot</FIRSTNAME><LASTNAME>Doherty</LASTNAME></AUTHOR><DATE><YEAR>2008</YEAR><MONTH>5</MONTH><DAY>7</DAY></DATE><COMMENT>Roche is betting on diabetes to compensate the future revenue reduction when its cancer drug patents will expire.</COMMENT></ARTICLE></ITEM>
    <ITEM><ARTICLE><X><T>Lilly's Science Grid Goes Open Source</T><A>http://www.bio-itworld.com/headlines/2008/05/lilly-grid-goes-open-source.html</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Kevin</FIRSTNAME><LASTNAME>Davies</LASTNAME></AUTHOR><DATE><YEAR>2008</YEAR><MONTH>5</MONTH><DAY>16</DAY></DATE><COMMENT>Lilly transforms its drug discovery framework into an open source project.</COMMENT></ARTICLE></ITEM>
    <ITEM><ARTICLE><X><T>Accelerating Intuition: Reynders on Big Challenges for Informatics</T><A>http://www.bio-itworld.com/2008/05/07/reynders-keynote-bioitworld-expo.html</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Catherine</FIRSTNAME><LASTNAME>Varmazis</LASTNAME></AUTHOR><DATE><YEAR>2008</YEAR><MONTH>5</MONTH><DAY>7</DAY></DATE><COMMENT>John Reynders, J&amp;J's CIO, explains that pharma companies need to be able to store vast amounts of data and mine them, to find connections in heterogeneous data types, to integrate innovation from outside the company, and, in the future, may get some help from artificial intelligence.</COMMENT></ARTICLE></ITEM>
    <ITEM><ARTICLE><X><T>Eugene Myers Prepares to BLAST Off Again</T><A>http://www.bio-itworld.com/pb/2008/10/23/eugene-myers-imaging-informatics.html</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>John</FIRSTNAME><LASTNAME>Russell</LASTNAME></AUTHOR><DATE><YEAR>2008</YEAR><MONTH>10</MONTH><DAY>23</DAY></DATE><COMMENT>An interview of Eugene Myers who is now working on huge microscopy imaging data.</COMMENT></ARTICLE></ITEM>
    <ITEM><ARTICLE><X><T>Agile IT Strategy in Pharmaceutical R&amp;D</T><A>http://www.bio-itworld.com/2009/issues/mar-apr/agile-it-in-pharma.html</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Andrew</FIRSTNAME><LASTNAME>Chadwick</LASTNAME></AUTHOR><DATE><YEAR>2009</YEAR><MONTH>3</MONTH><DAY>24</DAY></DATE><COMMENT>A pharma R&amp;D IT department needs some strategic goals. The author suggests some of them.</COMMENT></ARTICLE></ITEM>
    <ITEM><ARTICLE><X><T>Collaboration and the Long Tail of Disease</T><A>http://www.bio-itworld.com/issues/2009/mar-apr/first-base.html</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Kevin</FIRSTNAME><LASTNAME>Davies</LASTNAME></AUTHOR><DATE><YEAR>2009</YEAR><MONTH>3</MONTH><DAY>24</DAY></DATE><COMMENT>Jay Tenenbaum creates CollabRx so researchers can share their resources to help personalized medicine for diseases in the "long tail".</COMMENT></ARTICLE></ITEM>
    <ITEM><ARTICLE><X><T>Only Moore's Law Can Save Big Pharma</T><A>http://www.bio-itworld.com/2009/06/29/save-pharma-comment.html</A><L>en</L><F>HTML</F></X><AUTHOR><FIRSTNAME>Bill</FIRSTNAME><LASTNAME>Frezza</LASTNAME></AUTHOR><DATE><YEAR>2009</YEAR><MONTH>6</MONTH><DAY>29</DAY></DATE><COMMENT>The author advocates that pharma companies should design drugs instead of discovering them. This is science-fiction.</COMMENT></ARTICLE></ITEM>
  </BLIST></ITEM>
</LLIST>
</CONTENT>
</PAGE>

